Mesenchymal stem cell delivery strategies to promote cardiac regeneration following ischemic injury

Biomaterials

Volumn 35, Issue 13, 2014, Pages 3956-3974

  Russo, Valerio ^a,b   Young, Stuart ^a,b   Hamilton, Andrew ^b   Amsden, Brian G ^a,b   Flynn, Lauren E ^a,c,d  

^a QUEEN S UNIVERSITY   (Canada)

^b KINGSTON GENERAL HOSPITAL   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d WESTERN UNIVERSITY   (Canada)

Author keywords

Angiogenesis; Cardiac tissue engineering; Cell encapsulation; Injectable biomaterials; Mesenchymal stem cell

Indexed keywords

BONE; CELL CULTURE; HEART; STEM CELLS; TISSUE; TISSUE ENGINEERING;

ANGIOGENESIS; CARDIAC TISSUE ENGINEERING; CELL ENCAPSULATIONS; INJECTABLE BIOMATERIALS; MESENCHYMAL STEM CELL;

CELL ENGINEERING;

ALGINIC ACID; BIOMATERIAL; CHITOSAN; COLLAGEN; FIBRIN; HYALURONIC ACID; MACROGOL; MATRIGEL; POLY(N ISOPROPYLACRYLAMIDE); TISSUE SCAFFOLD;

ADIPOSE TISSUE; BIOMECHANICS; CELL DIFFERENTIATION; CELL INTERACTION; CELL MIGRATION; CELL SELECTION; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); EMBRYONIC STEM CELL; ENGRAFTMENT; HEART MUSCLE ISCHEMIA; HEMATOPOIETIC STEM CELL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN ASSEMBLY; REVIEW; TISSUE REGENERATION; UPREGULATION; ANIMAL; CYTOLOGY; HEART MUSCLE; MESENCHYMAL STROMA CELL; METABOLISM; MYOCARDIAL INFARCTION; PHYSIOLOGY; REGENERATION;

ANIMALIA;

ANIMALS; HUMANS; MESENCHYMAL STROMAL CELLS; MYOCARDIAL INFARCTION; MYOCARDIUM; REGENERATION;

EID: 84896705647     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.01.075     Document Type: Review

References (242)

1. Alwan A. Global status report on noncommunicable diseases 2010 2011, World Health Organization.
2. Go A.S., Mozaffarian D., Roger V.L., Benjamin E.J., Berry J.D., Borden W.B., et al. Executive summary: heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013, 127:143-152.
3. Sutton M.G., Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 2000, 101:2981-2988.
4. Weiss J.N., Qu Z., Chen P.-S., Lin S.-F., Karagueuzian H.S., Hayashi H., et al. The dynamics of cardiac fibrillation. Circulation 2005, 112:1232-1240.
5. Mukherjee D., Bhatt D.L., Roe M.T., Patel V., Ellis S.G. Direct myocardial revascularization and angiogenesis-how many patients might be eligible?. Am J Cardiol 1999, 84:598-600.
6. Kiernan T.J., Boilson B.A., Sandhu G.S., Lennon R.J., Roger V.L., Barsness G.W., et al. Nonrevascularizable coronary artery disease following coronary artery bypass graft surgery: a population-based study in Olmsted County, Minnesota. Coron Artery Dis 2009, 20:106-111.
7. Velagaleti R.S., Pencina M.J., Murabito J.M., Wang T.J., Parikh N.I., D'Agostino R.B., et al. Long-term trends in the incidence of heart failure after myocardial infarction. Circulation 2008, 118:2057-2062.
8. Collins M.C., Moore J.L., Burrows B.J., Kypson A.P., Muller-Borer B.J. Early cell loss associated with mesenchymal stem cell cardiomyoplasty. Open Tissue Eng Regen Med J 2012, 5:17-24.
9. Traverse J.H., McKenna D.H., Harvey K., Jorgenso B.C., Olson R.E., Bostrom N., et al. Results of a phase 1, randomized, double-blind, placebo-controlled trial of bone marrow mononuclear stem cell administration in patients following ST-elevation myocardial infarction. Am Heart J 2010, 160:428-434.
10. Wöhrle J., Merkle N., Mailänder V., Nusser T., Schauwecker P., Scheidt von F., et al. Results of intracoronary stem cell therapy after acute myocardial infarction. Am J Cardiol 2010, 105:804-812.
11. Lee J., Terracciano C.M. Cell therapy for cardiac repair. Br Med Bull 2010, 94:65-80.
12. Menasche P., Alfieri O., Janssens S., McKenna W., Reichenspurner H., Trinquart L., et al. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation 2008, 117:1189-1200.
13. Veltman C.E., Soliman O.I.I., Geleijnse M.L., Vletter W.B., Smits P.C., Cate ten F.J., et al. Four-year follow-up of treatment with intramyocardial skeletal myoblasts injection in patients with ischaemic cardiomyopathy. Eur Heart J 2008, 29:1386-1396.
14. Nussbaum J., Minami E., Laflamme M.A., Virag J.A.I., Ware C.B., Masino A., et al. Transplantation of undifferentiated murine embryonic stem cells in the heart: teratoma formation and immune response. FASEB J 2007, 21:1345-1357.
15. Bolli R., Chugh A.R., D'Amario D., Loughran J.H., Stoddard M.F., Ikram S., et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet 2011, 378:1847-1857.
16. Bearzi C., Rota M., Hosoda T., Tillmanns J., Nascimbene A., De Angelis A., et al. Human cardiac stem cells. Proc Natl Acad Sci U S A 2007, 104:14068-14073.
17. Hosoda T. C-kit-positive cardiac stem cells and myocardial regeneration. Am J Cardiovasc Dis 2012, 2:58-67.
18. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
19. Gimble J., Guilak F. Adipose-derived adult stem cells: isolation, characterization, and differentiation potential. Cytotherapy 2003, 5:362-369.
20. Fukumoto T., Sperling J.W., Sanyal A., Fitzsimmons J.S., Reinholz G.G., Conover C.A., et al. Combined effects of insulin-like growth factor-1 and transforming growth factor-beta1 on periosteal mesenchymal cells during chondrogenesis invitro. Osteoarthr Cartil 2003, 11:55-64.
21. De Bari C., Dell'Accio F., Tylzanowski P., Luyten F.P. Multipotent mesenchymal stem cells from adult human synovial membrane. Arthritis Rheum 2001, 44:1928-1942.
22. Jankowski R.J., Deasy B.M., Huard J. Muscle-derived stem cells. Gene Ther 2002, 9:642-647.
23. Miura M., Gronthos S., Zhao M., Lu B., Fisher L.W. Gehron Robey P. SHED: stem cells from human exfoliated deciduous teeth. Proc Natl Acad Sci U S A 2003, 100:5807-5812.
24. Castro-Malaspina H., Ebell W., Wang S. Human bone marrow fibroblast colony-forming units (CFU-F). Prog Clin Biol Res 1984, 154:209-236.
25. D'Ippolito G., Schiller P.C., Ricordi C., Roos B.A., Howard G.A. Age-related osteogenic potential of mesenchymal stromal stem cells from human vertebral bone marrow. JBone Miner Res 1999, 14:1115-1122.
26. Muschler G.F., Nitto H., Boehm C.A., Easley K.A. Age-and gender-related changes in the cellularity of human bone marrow and the prevalence of osteoblastic progenitors. JOrthop Res 2001, 19:117-125.
27. Mitchell J.B., McIntosh K., Zvonic S., Garrett S., Floyd Z.E., Kloster A., et al. Immunophenotype of human adipose-derived cells: temporal changes in stromal-associated and stem cell-associated markers. Stem Cells 2006, 24:376-385.
28. Fraser J.K., Wulur I., Alfonso Z., Zhu M., Wheeler E.S. Differences in stem and progenitor cell yield in different subcutaneous adipose tissue depots. Cytotherapy 2007, 9:459-467.
29. Maumus M., Peyrafitte J.-A., D'Angelo R., Fournier-Wirth C., Bouloumié A., Casteilla L., et al. Native human adipose stromal cells: localization, morphology and phenotype. Int J Obes (Lond) 2011, 35:1141-1153.
30. Noël D., Caton D., Roche S., Bony C., Lehmann S., Casteilla L., et al. Cell specific differences between human adipose-derived and mesenchymal-stromal cells despite similar differentiation potentials. Exp Cell Res 2008, 314:1575-1584.
31. De Ugarte D.A., Morizono K., Elbarbary A., Alfonso Z., Zuk P.A., Zhu M., et al. Comparison of multi-lineage cells from human adipose tissue and bone marrow. Cells Tissues Organs 2003, 174:101-109.
32. De Ugarte D.A., Alfonso Z., Zuk P.A., Elbarbary A., Zhu M., Ashjian P., et al. Differential expression of stem cell mobilization-associated molecules on multi-lineage cells from adipose tissue and bone marrow. Immunol Lett 2003, 89:267-270.
33. Yañez R., Lamana M.L., García-Castro J., Colmenero I., Ramírez M., Bueren J.A. Adipose tissue-derived mesenchymal stem cells have invivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells 2006, 24:2582-2591.
34. Pachón-Peña G., Yu G., Tucker A., Wu X., Vendrell J., Bunnell B.A., et al. Stromal stem cells from adipose tissue and bone marrow of age-matched female donors display distinct immunophenotypic profiles. JCell Physiol 2011, 226:843-851.
35. Kern S., Eichler H., Stoeve J., Klüter H., Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 2006, 24:1294-1301.
36. Rebelatto C.K., Aguiar A.M., Moretao M.P., Senegaglia A.C., Hansen P., Barchiki F., et al. Dissimilar differentiation of mesenchymal stem cells from bone marrow, umbilical cord blood, and adipose tissue. Exp Biol Med (Maywood) 2008, 233:901-913.
37. Hare J.M., Traverse J.H., Henry T.D., Dib N., Strumpf R.K., Schulman S.P., et al. Arandomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. JAm Coll Cardiol 2009, 54:2277-2286.
38. Izadpanah R., Trygg C., Patel B., Kriedt C., Dufour J., Gimble J.M., et al. Biologic properties of mesenchymal stem cells derived from bone marrow and adipose tissue. JCell Biochem 2006, 99:1285-1297.
39. Paul A., Srivastava S., Chen G., Shum-Tim D., Prakash S. Functional assessment of adipose stem cells for xenotransplantation using myocardial infarction immunocompetent models: comparison with bone marrow stem cells. Cell Biochem Biophys 2013, 67:263-273.
40. Kim Y., Kim H., Cho H., Bae Y., Suh K., Jung J. Direct comparison of human mesenchymal stem cells derived from adipose tissues and bone marrow in mediating neovascularization in response to vascular ischemia. Cell Physiol Biochem 2007, 20:867-876.
41. Bochev I., Elmadjian G., Kyurkchiev D., Tzvetanov L., Altankova I., Tivchev P., et al. Mesenchymal stem cells from human bone marrow or adipose tissue differently modulate mitogen-stimulated B-cell immunoglobulin production invitro. Cell Biol Int 2008, 32:384-393.
42. Ivanova-Todorova E., Bochev I., Mourdjeva M., Dimitrov R., Bukarev D., Kyurkchiev S., et al. Adipose tissue-derived mesenchymal stem cells are more potent suppressors of dendritic cells differentiation compared to bone marrow-derived mesenchymal stem cells. Immunol Lett 2009, 126:37-42.
43. Melief S.M., Zwaginga J.J., Fibbe W.E., Roelofs H. Adipose tissue-derived multipotent stromal cells have a higher immunomodulatory capacity than their bone marrow-derived counterparts. Stem Cells Transl Med 2013, 2:455-463.
44. Breitbach M., Bostani T., Roell W., Xia Y., Dewald O., Nygren J.M., et al. Potential risks of bone marrow cell transplantation into infarcted hearts. Blood 2007, 110:1362-1369.
45. Baglioni S., Cantini G., Poli G., Francalanci M., Squecco R., Di Franco A., et al. Functional differences in visceral and subcutaneous fat pads originate from differences in the adipose stem cell. PLoS One 2012, 7:e36569.
46. Park H.T., Lee E.S., Cheon Y.-P., Lee D.R., Yang K.-S., Kim Y.T., et al. The relationship between fat depot-specific preadipocyte differentiation and metabolic syndrome in obese women. Clin Endocrinol 2012, 76:59-66.
47. Russo V., Yu C., Belliveau P., Hamilton A., Flynn L.E. Comparison of human adipose-derived stem cells isolated from subcutaneous, Omental, and Intrathoracic adipose tissue depots for regenerative applications. Stem Cells Transl Med 2013, Available from:. http://stemcellstm.alphamedpress.org/content/early/2013/12/19/sctm.2013-0125, 10.5966/sctm.2013-0125.
48. Friedenstein A.J., Gorskaja J.F., Kulagina N.N. Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Exp Hematol 1976, 4:267-274.
49. Reyes M., Lund T., Lenvik T., Aguiar D., Koodie L., Verfaillie C.M. Purification and exvivo expansion of postnatal human marrow mesodermal progenitor cells. Blood 2001, 98:2615-2625.
50. Mosna F., Sensebé L., Krampera M. Human bone marrow and adipose tissue mesenchymal stem cells: a user's guide. Stem Cells Dev 2010, 19:1449-1470.
51. Tomita S., Li R.K., Weisel R.D., Mickle D.A.G., Kim E.J., Sakai T., et al. Autologous transplantation of bone marrow cells improves damaged heart function. Circulation 1999, 100. II-247-II-256.
52. Kamihata H., Matsubara H., Nishiue T., Fujiyama S., Tsutsumi Y., Ozono R., et al. Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation 2001, 104:1046-1052.
53. Tang Y.L., Zhao Q., Zhang Y.C., Cheng L., Liu M., Shi J., et al. Autologous mesenchymal stem cell transplantation induce VEGF and neovascularization in ischemic myocardium. Regul Pept 2004, 117:3-10.
54. Zhang S., Guo J., Zhang P., Liu Y., Jia Z., Ma K., et al. Long-term effects of bone marrow mononuclear cell transplantation on left ventricular function and remodeling in rats. Life Sci 2004, 74:2853-2864.
55. Tang J., Xie Q., Pan G., Wang J., Wang M. Mesenchymal stem cells participate in angiogenesis and improve heart function in rat model of myocardial ischemia with reperfusion. Eur J Cardiothorac Surg 2006, 30:353-361.
56. Orlic D., Kajstura J., Chimenti S., Jakoniuk I., Anderson S.M., Li B., et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001, 410:701-705.
57. Kudo M., Wang Y., Wani M.A., Xu M., Ayub A., Ashraf M. Implantation of bone marrow stem cells reduces the infarction and fibrosis in ischemic mouse heart. JMol Cell Cardiol 2003, 35:1113-1119.
58. Kajstura J., Rota M., Whang B., Cascapera S., Hosoda T., Bearzi C., et al. Bone marrow cells differentiate in cardiac cell lineages after infarction independently of cell fusion. Circ Res 2005, 96:127-137.
59. Rota M., Kajstura J., Hosoda T., Bearzi C., Vitale S., Esposito G., et al. Bone marrow cells adopt the cardiomyogenic fate invivo. Proc Natl Acad Sci U S A 2007, 104:17783-17788.
60. Shake J.G., Gruber P.J., Baumgartner W.A., Senechal G., Meyers J., Redmond J.M., et al. Mesenchymal stem cell implantation in a swine myocardial infarct model: engraftment and functional effects. Ann Thorac Surg 2002, 73:1919-1925. discussion1926.
61. Silva G.V., Litovsky S., Assad J.A.R., Sousa A.L.S., Martin B.J., Vela D., et al. Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model. Circulation 2005, 111:150-156.
62. Gimble J.M., Katz A.J., Bunnell B.A. Adipose-derived stem cells for regenerative medicine. Circ Res 2007, 100:1249-1260.
63. Nishida S., Endo N., Yamagiwa H., Tanizawa T., Takahashi H.E. Number of osteoprogenitor cells in human bone marrow markedly decreases after skeletal maturation. JBone Miner Metab 1999, 17:171-177.
64. Stenderup K., Justesen J., Eriksen E.F., Rattan S.I., Kassem M. Number and proliferative capacity of osteogenic stem cells are maintained during aging and in patients with osteoporosis. JBone Miner Res 2001, 16:1120-1129.
65. Miyahara Y., Nagaya N., Kataoka M., Yanagawa B., Tanaka K., Hao H., et al. Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction. Nat Med 2006, 12:459-465.
66. Mazo M., Planat-Bénard V., Abizanda G., Pelacho B., Léobon B., Gavira J.J., et al. Transplantation of adipose derived stromal cells is associated with functional improvement in a rat model of chronic myocardial infarction. Eur J Heart Fail 2008, 10:454-462.
67. Schenke-Layland K., Strem B.M., Jordan M.C., Deemedio M.T., Hedrick M.H., Roos K.P., et al. Adipose tissue-derived cells improve cardiac function following myocardial infarction. JSurg Res 2009, 153:217-223.
68. Wang L., Deng J., Tian W., Xiang B., Yang T., Li G., et al. Adipose-derived stem cells are an effective cell candidate for treatment of heart failure: an MR imaging study of rat hearts. Am J Physiol Heart Circ Physiol 2009, 297:H1020-H1031.
69. Cai L., Johnstone B.H., Cook T.G., Tan J., Fishbein M.C., Chen P.-S., et al. IFATS collection: human adipose tissue-derived stem cells induce angiogenesis and nerve sprouting following myocardial infarction, in conjunction with potent preservation of cardiac function. Stem Cells 2009, 27:230-237.
70. Bayes-Genis A., Soler-Botija C., Farré J., Sepúlveda P., Raya A., Roura S., et al. Human progenitor cells derived from cardiac adipose tissue ameliorate myocardial infarction in rodents. JMol Cell Cardiol 2010, 49:771-780.
71. Bai X., Yan Y., Song Y.H., Seidensticker M., Rabinovich B., Metzele R., et al. Both cultured and freshly isolated adipose tissue-derived stem cells enhance cardiac function after acute myocardial infarction. Eur Heart J 2010, 31:489-501.
72. Valina C., Pinkernell K., Song Y.H., Bai X., Sadat S., Campeau R.J., et al. Intracoronary administration of autologous adipose tissue-derived stem cells improves left ventricular function, perfusion, and remodelling after acute myocardial infarction. Eur Heart J 2007, 28:2667-2677.
73. Alt E., Pinkernell K., Scharlau M., Coleman M., Fotuhi P., Nabzdyk C., et al. Effect of freshly isolated autologous tissue resident stromal cells on cardiac function and perfusion following acute myocardial infarction. Int J Cardiol 2010, 144:26-35.
74. Zhang D.-Z., Gai L.-Y., Liu H.-W., Jin Q.-H., Huang J.-H., Zhu X.-Y. Transplantation of autologous adipose-derived stem cells ameliorates cardiac function in rabbits with myocardial infarction. Chin Med J (Engl) 2007, 120:300.
75. Gronthos S., Franklin D.M., Leddy H.A., Robey P.G., Storms R.W., Gimble J.M. Surface protein characterization of human adipose tissue-derived stromal cells. JCell Physiol 2001, 189:54-63.
76. Pittenger M.F., Martin B.J. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res 2004, 95:9-20.
77. Hoover-Plow J., Gong Y. Challenges for heart disease stem cell therapy. Vasc Health Risk Manag 2012, 8:99-113.
78. Baek S.J., Kang S.K., Ra J.C. Invitro migration capacity of human adipose tissue-derived mesenchymal stem cells reflects their expression of receptors for chemokines and growth factors. Exp Mol Med 2011, 43:596-603.
79. Ma J., Zhang S., Sun A., Shen J., Chen L., Wang K., et al. Time course of myocardial stromal cell-derived factor 1 expression and beneficial effects of intravenously administered bone marrow stem cells in rats with experimental myocardial infarction. Basic Res Cardiol 2005, 100:217-223.
80. Son B.R., Marquez Curtis L.A., Kucia M., Wysoczynski M., Turner A.R., Ratajczak J., et al. Migration of bone marrow and cord blood mesenchymal stem cells invitro is regulated by stromal-derived factor-1-CXCR4 and hepatocyte growth factor-c-met axes and involves matrix metalloproteinases. Stem Cells 2006, 24:1254-1264.
81. Bhakta S., Hong P., Koc O. The surface adhesion molecule CXCR4 stimulates mesenchymal stem cell migration to stromal cell-derived factor-1 invitro but does not decrease apoptosis under serum deprivation. Cardiovasc Revasc Med 2006, 7:19-24.
82. Ceradini D.J., Kulkarni A.R., Callaghan M.J., Tepper O.M., Bastidas N., Kleinman M.E., et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004, 10:858-864.
83. Wojakowski W., Tendera M., Michałowska A., Majka M., Kucia M., Maślankiewicz K., et al. Mobilization of CD34/CXCR4+, CD34/CD117+, c-met+ stem cells, and mononuclear cells expressing early cardiac, muscle, and endothelial markers into peripheral blood in patients with acute myocardial infarction. Circulation 2004, 110:3213-3220.
84. Kinnaird T., Stabile E., Burnett M.S., Lee C.W., Barr S., Fuchs S., et al. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote invitro and invivo arteriogenesis through paracrine mechanisms. Circ Res 2004, 94:678-685.
85. Kinnaird T., Stabile E., Burnett M.S., Shou M., Lee C.W., Barr S., et al. Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation 2004, 109:1543-1549.
86. Kobayashi T., Hamano K., Li T.-S., Katoh T., Kobayashi S., Matsuzaki M., et al. Enhancement of angiogenesis by the implantation of self bone marrow cells in a rat ischemic heart model. JSurg Res 2000, 89:189-195.
87. Liechty K.W., MacKenzie T.C., Shaaban A.F., Radu A., Moseley A.M., Deans R., et al. Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat Med 2000, 6:1282-1286.
88. Bartholomew A., Sturgeon C., Siatskas M., Ferrer K., McIntosh K., Patil S., et al. Mesenchymal stem cells suppress lymphocyte proliferation invitro and prolong skin graft survival invivo. Exp Hematol 2002, 30:42-48.
89. Aggarwal S., Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005, 105:1815-1822.
90. McIntosh K., Zvonic S., Garrett S., Mitchell J.B., Floyd Z.E., Hammill L., et al. The immunogenicity of human adipose-derived cells: temporal changes invitro. Stem Cells 2006, 24:1246-1253.
91. Yoon Y.-S., Wecker A., Heyd L., Park J.-S., Tkebuchava T., Kusano K., et al. Clonally expanded novel multipotent stem cells from human bone marrow regenerate myocardium after myocardial infarction. JClin Invest 2005, 115:326-338.
92. Makino S., Fukuda K., Miyoshi S., Konishi F., Kodama H., Pan J., et al. Cardiomyocytes can be generated from marrow stromal cells invitro. JClin Invest 1999, 103:697-705.
93. Xu W., Zhang X., Qian H., Zhu W., Sun X., Hu J., et al. Mesenchymal stem cells from adult human bone marrow differentiate into a cardiomyocyte phenotype invitro. Exp Biol Med (Maywood) 2004, 229:623-631.
94. Shim W.S.N., Jiang S., Wong P., Tan J., Chua Y.L., Tan Y.S., et al. Exvivo differentiation of human adult bone marrow stem cells into cardiomyocyte-like cells. Biochem Biophys Res Commun 2004, 324:481-488.
95. Rangappa S., Fen C., Lee E.H., Bongso A., Sim E.K.W., Wei E.K.S. Transformation of adult mesenchymal stem cells isolated from the fatty tissue into cardiomyocytes. Ann Thorac Surg 2003, 75:775-779.
96. Dijk A., Niessen H.W.M., Zandieh Doulabi B., Visser F.C., Milligen F.J. Differentiation of human adipose-derived stem cells towards cardiomyocytes is facilitated by laminin. Cell Tissue Res 2008, 334:457-467.
97. Planat-Bénard V., Menard C., André M., Puceat M., Perez A., Garcia-Verdugo J.-M., et al. Spontaneous cardiomyocyte differentiation from adipose tissue stroma cells. Circ Res 2004, 94:223-229.
98. Sliwa A., Balwierz A., Kiec-Wilk B., Polus A., Knapp A., Dembinska-Kiec A. Differentiation of human adipose tissue SVF cells into cardiomyocytes. Genes Nutr 2009, 4:195-198.
99. Oswald J., Boxberger S., Jørgensen B., Feldmann S., Ehninger G., Bornhäuser M., et al. Mesenchymal stem cells can be differentiated into endothelial cells invitro. Stem Cells 2004, 22:377-384.
100. Chen M.-Y., Lie P.-C., Li Z.-L., Wei X. Endothelial differentiation of Wharton's jelly-derived mesenchymal stem cells in comparison with bone marrow-derived mesenchymal stem cells. Exp Hematol 2009, 37:629-640.
101. Colazzo F., Chester A.H., Taylor P.M., Yacoub M.H. Induction of mesenchymal to endothelial transformation of adipose-derived stem cells. JHeart Valve Dis 2010, 19:736-744.
102. Ning H., Liu G., Lin G., Yang R., Lue T.F., Lin C.-S. Fibroblast growth factor 2 promotes endothelial differentiation of adipose tissue-derived stem cells. JSex Med 2009, 6:967-979.
103. Kinner B., Zaleskas J.M., Spector M. Regulation of smooth muscle actin expression and contraction in adult human mesenchymal stem cells. Exp Cell Res 2002, 278:72-83.
104. Rodriguez L.V., Alfonso Z., Zhang R., Leung J., Wu B., Ignarro L.J. Clonogenic multipotent stem cells in human adipose tissue differentiate into functional smooth muscle cells. Proc Natl Acad Sci U S A 2006, 103:12167-12172.
105. Yang J., Song T., Wu P., Chen Y., Fan X., Chen H., et al. Differentiation potential of human mesenchymal stem cells derived from adipose tissue and bone marrow to sinus node-like cells. Mol Med Rep 2012, 5:108-113.
106. Liu Y., Song J., Liu W., Wan Y., Chen X., Hu C. Growth and differentiation of rat bone marrow stromal cells: does 5-azacytidine trigger their cardiomyogenic differentiation?. Cardiovasc Res 2003, 58:460-468.
107. Rangappa S., Entwistle J.W.C., Wechsler A.S., Kresh J.Y. Cardiomyocyte-mediated contact programs human mesenchymal stem cells to express cardiogenic phenotype. JThorac Cardiovasc Surg 2003, 126:124-132.
108. Zhu Y., Liu T., Song K., Ning R., Ma X., Cui Z. ADSCs differentiated into cardiomyocytes in cardiac microenvironment. Mol Cell Biochem 2008, 324:117-129.
109. Plotnikov E.Y., Khryapenkova T.G., Vasileva A.K., Marey M.V., Galkina S.I., Isaev N.K., et al. Cell-to-cell cross-talk between mesenchymal stem cells and cardiomyocytes in co-culture. JCell Mol Med 2008, 12:1622-1631.
110. Metzele R., Alt C., Bai X., Yan Y., Zhang Z., Pan Z., et al. Human adipose tissue-derived stem cells exhibit proliferation potential and spontaneous rhythmic contraction after fusion with neonatal rat cardiomyocytes. FASEB J 2011, 25:830-839.
111. Perán M., Marchal J.A., López E., Jiménez-Navarro M., Boulaiz H., Rodríguez-Serrano F., et al. Human cardiac tissue induces transdifferentiation of adult stem cells towards cardiomyocytes. Cytotherapy 2010, 12:332-337.
112. Ramesh B., Bishi D.K., Rallapalli S., Arumugam S., Cherian K.M., Guhathakurta S. Ischemic cardiac tissue conditioned media induced differentiation of human mesenchymal stem cells into early stage cardiomyocytes. Cytotechnology 2012, 64:563-575.
113. Alvarez-Dolado M., Pardal R., Garcia-Verdugo J.M., Fike J.R., Lee H.O., Pfeffer K., et al. Fusion of bone-marrow-derived cells with Purkinje neurons, cardiomyocytes and hepatocytes. Nature 2003, 425:968-973.
114. Scherschel J.A., Soonpaa M.H., Srour E.F., Field L.J., Rubart M. Adult bone marrow-derived cells do not acquire functional attributes of cardiomyocytes when transplanted into peri-infarct myocardium. Mol Ther 2008, 16:1129-1137.
115. Yoon C.-H., Koyanagi M., Iekushi K., Seeger F., Urbich C., Zeiher A.M., et al. Mechanism of improved cardiac function after bone marrow mononuclear cell therapy: role of cardiovascular lineage commitment. Circulation 2010, 121:2001-2011.
116. Sadat S., Gehmert S., Song Y.-H., Yen Y., Bai X., Gaiser S., et al. The cardioprotective effect of mesenchymal stem cells is mediated by IGF-I and VEGF. Biochem Biophys Res Commun 2007, 363:674-679.
117. Rehman J., Traktuev D., Li J., Merfeld-Clauss S., Temm-Grove C.J., Bovenkerk J.E., et al. Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation 2004, 109:1292-1298.
118. Uemura R., Xu M., Ahmad N., Ashraf M. Bone marrow stem cells prevent left ventricular remodeling of ischemic heart through paracrine signaling. Circ Res 2006, 98:1414-1421.
119. Nakagami H., Maeda K., Morishita R., Iguchi S., Nishikawa T., Takami Y., et al. Novel autologous cell therapy in ischemic limb disease through growth factor secretion by cultured adipose tissue-derived stromal cells. Arterioscler Thromb Vasc Biol 2005, 25:2542-2547.
120. Fazel S., Cimini M., Chen L., Li S., Angoulvant D., Fedak P., et al. Cardioprotective c-kit+ cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines. JClin Invest 2006, 116:1865-1877.
121. Moon M.H., Kim S.Y., Kim Y.J., Kim S.J., Lee J.B., Bae Y.C., et al. Human adipose tissue-derived mesenchymal stem cells improve postnatal neovascularization in a mouse model of hindlimb ischemia. Cell Physiol Biochem 2006, 17:279-290.
122. Majumdar M.K., Thiede M.A., Mosca J.D., Moorman M., Gerson S.L. Phenotypic and functional comparison of cultures of marrow-derived mesenchymal stem cells (MSCs) and stromal cells. JCell Physiol 1998, 176:57-66.
123. Weimar I.S., Miranda N., Muller E.J., Hekman A., Kerst J.M., de Gast G.C., et al. Hepatocyte growth factor/scatter factor (HGF/SF) is produced by human bone marrow stromal cells and promotes proliferation, adhesion and survival of human hematopoietic progenitor cells (CD34+). Exp Hematol 1998, 26:885-894.
124. Anderson C.D., Heydarkhan-Hagvall S., Schenke-Layland K., Yang J.Q., Jordan M.C., Kim J.K., et al. The role of cytoprotective cytokines in cardiac ischemia/reperfusion injury. JSurg Res 2008, 148:164-171.
125. Cheng S.L., Zhang S.F., Mohan S., Lecanda F., Fausto A., Hunt A.H., et al. Regulation of insulin-like growth factors I and II and their binding proteins in human bone marrow stromal cells by dexamethasone. JCell Biochem 1998, 71:449-458.
126. Markel T.A., Wang Y., Herrmann J.L., Crisostomo P.R., Wang M., Novotny N.M., et al. VEGF is critical for stem cell-mediated cardioprotection and a crucial paracrine factor for defining the age threshold in adult and neonatal stem cell function. Am J Physiol Heart Circ Physiol 2008, 295:H2308-H2314.
127. Bobis-Wozowicz S., Miekus K., Wybieralska E., Jarocha D., Zawisz A., Madeja Z., et al. Genetically modified adipose tissue-derived mesenchymal stem cells overexpressing CXCR4 display increased motility, invasiveness, and homing to bone marrow of NOD/SCID mice. Exp Hematol 2011, 39. 686-696.e4.
128. Cheng Z., Ou L., Zhou X., Li F., Jia X., Zhang Y., et al. Targeted migration of mesenchymal stem cells modified with cxcr4 gene to infarcted myocardium improves cardiac performance. Mol Ther 2008, 16:571-579.
129. Haider H.K., Jiang S., Idris N.M., Ashraf M. IGF-1-overexpressing mesenchymal stem cells accelerate bone marrow stem cell mobilization via paracrine activation of SDF-1α/CXCR4 signaling to promote myocardial repair. Circ Res 2008, 103:1300-1308.
130. Huang J., Zhang Z., Guo J., Ni A., Deb A., Zhang L., et al. Genetic modification of mesenchymal stem cells overexpressing CCR1 increases cell viability, migration, engraftment, and capillary density in the injured myocardium. Circ Res 2010, 106:1753-1762.
131. Wang W.E., Yang D., Li L., Wang W., Peng Y., Chen C., et al. Prolyl hydroxylase domain protein 2 silencing enhances the survival and paracrine function of transplanted adipose-derived stem cells in infarcted myocardium. Circ Res 2013, 113:288-300.
132. Wood S.M., Wiesener M.S., Yeates K.M., Okada N., Pugh C.W., Maxwell P.H., et al. Selection and analysis of a mutant cell line defective in the hypoxia-inducible factor-1 alpha-subunit (HIF-1alpha). Characterization of hif-1alpha-dependent and -independent hypoxia-inducible gene expression. JBiol Chem 1998, 273:8360-8368.
133. Iyer N.V., Kotch L.E., Agani F., Leung S.W., Laughner E., Wenger R.H., et al. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1α. Genes Dev 1998, 12:149-162.
134. Tazuke S.I., Mazure N.M., Sugawara J., Carland G., Faessen G.H., Suen L.F., et al. Hypoxia stimulates insulin-like growth factor binding protein 1 (IGFBP-1) gene expression in HepG2 cells: a possible model for IGFBP-1 expression in fetal hypoxia. Proc Natl Acad Sci U S A 1998, 95:10188-10193.
135. Feldser D., Agani F., Iyer N.V., Pak B., Ferreira G., Semenza G.L. Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res 1999, 59:3915-3918.
136. Oh J.S., Ha Y., An S.S., Khan M., Pennant W.A., Kim H.J., et al. Hypoxia-preconditioned adipose tissue-derived mesenchymal stem cell increase the survival and gene expression of engineered neural stem cells in a spinal cord injury model. Neurosci Lett 2010, 472:215-219.
137. Carmeliet P., Dor Y., Herbert J.M., Fukumura D., Brusselmans K., Dewerchin M., et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998, 394:485-490.
138. Marti H.J., Bernaudin M., Bellail A., Schoch H., Euler M., Petit E., et al. Hypoxia-induced vascular endothelial growth factor expression precedes neovascularization after cerebral ischemia. Am J Pathol 2000, 156:965-976.
139. Gerber H.P., Condorelli F., Park J., Ferrara N. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. JBiol Chem 1997, 272:23659-23667.
140. Ryan H.E., Lo J., Johnson R.S. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J 1998, 17:3005-3015.
141. Lee E.Y., Xia Y., Kim W.-S., Kim M.H., Kim T.H., Kim K.J., et al. Hypoxia-enhanced wound-healing function of adipose-derived stem cells: increase in stem cell proliferation and up-regulation of VEGF and bFGF. Wound Repair Regen 2009, 17:540-547.
142. Kubo M., Li T.-S., Kurazumi H., Takemoto Y., Ohshima M., Murata T., et al. Hypoxic preconditioning enhances angiogenic potential of bone marrow cells with aging-related functional impairment. Circ J 2012, 76:986-994.
143. Kubo M., Li T.S., Suzuki R., Shirasawa B., Morikage N., Ohshima M., et al. Hypoxic preconditioning increases survival and angiogenic potency of peripheral blood mononuclear cells via oxidative stress resistance. Am J Physiol Heart Circ Physiol 2008, 294:H590-H595.
144. Chacko S.M., Ahmed S., Selvendiran K., Kuppusamy M.L., Khan M., Kuppusamy P. Hypoxic preconditioning induces the expression of prosurvival and proangiogenic markers in mesenchymal stem cells. Am J Physiol Cell Physiol 2010, 299:C1562-C1570.
145. Stubbs S.L., Hsiao S.T.-F., Peshavariya H.M., Lim S.Y., Dusting G.J., Dilley R.J. Hypoxic preconditioning enhances survival of human adipose-derived stem cells and conditions endothelial cells invitro. Stem Cells Dev 2012, 21:1887-1896.
146. Rosová I., Dao M., Capoccia B., Link D., Nolta J.A. Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells. Stem Cells 2008, 26:2173-2182.
147. Tang Y.L., Zhu W., Cheng M., Chen L., Zhang J., Sun T., et al. Hypoxic preconditioning enhances the benefit of cardiac progenitor cell therapy for treatment of myocardial infarction by inducing CXCR4 expression. Circ Res 2009, 104:1209-1216.
148. Hu X., Yu S.P., Fraser J.L., Lu Z., Ogle M.E., Wang J.-A., et al. Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis. JThorac Cardiovasc Surg 2008, 135:799-808.
149. Strauer B.E., Brehm M., Zeus T., Köstering M., Hernandez A., Sorg R.V., et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 2002, 106:1913-1918.
150. Schächinger V., Erbs S., Elsässer A., Haberbosch W., Hambrecht R., Hölschermann H., et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. NEngl J Med 2006, 355:1210-1221.
151. Meyer G.P., Wollert K.C., Lotz J., Steffens J., Lippolt P., Fichtner S., et al. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation 2006, 113:1287-1294.
152. Assmus B., Schächinger V., Teupe C., Britten M., Lehmann R., Döbert N., et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation 2002, 106:3009-3017.
153. Assmus B., Honold J., Schächinger V., Britten M.B., Fischer-Rasokat U., Lehmann R., et al. Transcoronary transplantation of progenitor cells after myocardial infarction. NEngl J Med 2006, 355:1222-1232.
154. Janssens S., Dubois C., Bogaert J., Theunissen K., Deroose C., Desmet W., et al. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet 2006, 367:113-121.
155. Roncalli J., Mouquet F., Piot C., Trochu J.N., Le Corvoisier P., Neuder Y., et al. Intracoronary autologous mononucleated bone marrow cell infusion for acute myocardial infarction: results of the randomized multicenter BONAMI trial. Eur Heart J 2011, 32:1748-1757.
156. Lunde K., Solheim S., Aakhus S., Arnesen H., Abdelnoor M., Egeland T., et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. NEngl J Med 2006, 355:1199-1209.
157. Meyer G.P., Wollert K.C., Lotz J., Pirr J., Rager U., Lippolt P., et al. Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial. Eur Heart J 2009, 30:2978-2984.
158. Leistner D.M., Fischer-Rasokat U., Honold J., Seeger F.H., Schächinger V., Lehmann R., et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI): final 5-year results suggest long-term safety and efficacy. Clin Res Cardiol 2011, 100:925-934.
159. Houtgraaf J.H., Dekker den W.K., van Dalen B.M., Springeling T., de Jong R., van Geuns R.J., et al. First experience in humans using adipose tissue-derived regenerative cells in the treatment of patients with ST-segment elevation myocardial infarction. JAm Coll Cardiol 2012, 59:539-540.
160. Perin E.C., Sanchez P.L., Ruiz R.S., Perez-Cano R., Lasso J., Alonso-Farto J.C., et al. First in man transendocardial injection of autologous adipose-derived stem cells in patients with non revascularizable ischemic myocardium (PRECISE). Circulation 2010, 112:A17966.
161. Qayyum A.A., Haack-Sørensen M., Mathiasen A.B., Jørgensen E., Ekblond A., Kastrup J. Adipose-derived mesenchymal stromal cells for chronic myocardial ischemia (MyStromalCell Trial): study design. Regen Med 2012, 7:421-428.
162. Laflamme M.A., Murry C.E. Heart regeneration. Nature 2011, 473:326-335.
163. Wollert K.C., Meyer G.P., Lotz J., Ringes-Lichtenberg S., Lippolt P., Breidenbach C., et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 2004, 364:141-148.
164. Hou D., Youssef E.A.-S., Brinton T.J., Zhang P., Rogers P., Price E.T., et al. Radiolabeled cell distribution after intramyocardial, intracoronary, and interstitial retrograde coronary venous delivery: implications for current clinical trials. Circulation 2005, 112:I150-I156.
165. Pijnappels D.A., Gregoire S., Wu S.M. The integrative aspects of cardiac physiology and their implications for cell-based therapy. Ann N Y Acad Sci 2010, 1188:7-14.
166. van der Bogt K.E.A., Schrepfer S., Yu J., Sheikh A.Y., Hoyt G., Govaert J.A., et al. Comparison of transplantation of adipose tissue- and bone marrow-derived mesenchymal stem cells in the infarcted heart. Transplantation 2009, 87:642-652.
167. Tang Y.L., Tang Y., Zhang Y.C., Qian K., Shen L., Phillips M.I. Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector. JAm Coll Cardiol 2005, 46:1339-1350.
168. Frangogiannis N.G., Entman M.L. Chemokines in myocardial ischemia. Trends Cardiovasc Med 2005, 15:163-169.
169. Wang F., Guan J. Cellular cardiomyoplasty and cardiac tissue engineering for myocardial therapy. Adv Drug Deliv Rev 2010, 62:784-797.
170. Reeve J.L.V., Duffy A.M., O'Brien T., Samali A. Don't lose heart-therapeutic value of apoptosis prevention in the treatment of cardiovascular disease. JCell Mol Med 2005, 9:609-622.
171. Hu X., Wang J., Chen J., Luo R., He A., Xie X., et al. Optimal temporal delivery of bone marrow mesenchymal stem cells in rats with myocardial infarction. Eur J Cardiothorac Surg 2007, 31:438-443.
172. Van Linthout S., Savvatis K., Miteva K., Peng J., Ringe J., Warstat K., et al. Mesenchymal stem cells improve murine acute coxsackievirus B3-induced myocarditis. Eur Heart J 2011, 32:2168-2178.
173. Landa N., Miller L., Feinberg M.S., Holbova R., Shachar M., Freeman I., et al. Effect of injectable alginate implant on cardiac remodeling and function after recent and old infarcts in rat. Circulation 2008, 117:1388-1396.
174. Leor J., Tuvia S., Guetta V., Manczur F., Castel D., Willenz U., et al. Intracoronary injection of in situ forming alginate hydrogel reverses left ventricular remodeling after myocardial infarction in swine. JAm Coll Cardiol 2009, 54:1014-1023.
175. Tsur-Gang O., Ruvinov E., Landa N., Holbova R., Feinberg M.S., Leor J., et al. The effects of peptide-based modification of alginate on left ventricular remodeling and function after myocardial infarction. Biomaterials 2009, 30:189-195.
176. Yu J., Du K.T., Fang Q., Gu Y., Mihardja S.S., Sievers R.E., et al. The use of human mesenchymal stem cells encapsulated in RGD modified alginate microspheres in the repair of myocardial infarction in the rat. Biomaterials 2010, 31:7012-7020.
177. Lu W.-N., Lü S.-H., Wang H.-B., Li D.-X., Duan C.-M., Liu Z.-Q., et al. Functional improvement of infarcted heart by co-injection of embryonic stem cells with temperature-responsive chitosan hydrogel. Tissue Eng Part A 2009, 15:1437-1447.
178. Liu Z., Wang H., Wang Y., Lin Q., Yao A., Cao F., et al. The influence of chitosan hydrogel on stem cell engraftment, survival and homing in the ischemic myocardial microenvironment. Biomaterials 2012, 33:3093-3106.
179. Dai W., Wold L.E., Dow J.S., Kloner R.A. Thickening of the infarcted wall by collagen injection improves left ventricular function in rats. JAm Coll Cardiol 2005, 46:714-719.
180. Dai W., Hale S.L., Kay G.L., Jyrala A.J., Kloner R.A. Delivering stem cells to the heart in a collagen matrix reduces relocation of cells to other organs as assessed by nanoparticle technology. Regen Med 2009, 4:387-395.
181. Christman K.L., Fok H.H., Sievers R.E., Fang Q., Lee R.J. Fibrin glue alone and skeletal myoblasts in a fibrin scaffold preserve cardiac function after myocardial infarction. Tissue Eng 2004, 10:403-409.
182. Zhang G., Hu Q., Braunlin E.A., Suggs L.J., Zhang J. Enhancing efficacy of stem cell transplantation to the heart with a PEGylated fibrin biomatrix. Tissue Eng Part A 2008, 14:1025-1036.
183. Zhang X., Wang H., Ma X., Adila A., Wang B., Liu F., et al. Preservation of the cardiac function in infarcted rat hearts by the transplantation of adipose-derived stem cells with injectable fibrin scaffolds. Exp Biol Med 2010, 235:1505-1515.
184. Ifkovits J.L., Tous E., Minakawa M., Morita M., Robb J.D., Koomalsingh K.J., et al. Injectable hydrogel properties influence infarct expansion and extent of postinfarction left ventricular remodeling in an ovine model. Proc Natl Acad Sci U S A 2010, 107:11507-11512.
185. Tous E., Ifkovits J.L., Koomalsingh K.J., Shuto T., Soeda T., Kondo N., et al. Influence of injectable hyaluronic acid hydrogel degradation behavior on infarction-induced ventricular remodeling. Biomacromolecules 2011, 12:4127-4135.
186. Kofidis T., Lebl D.R., Martinez E.C., Hoyt G., Tanaka M., Robbins R.C. Novel injectable bioartificial tissue facilitates targeted, less invasive, large-scale tissue restoration on the beating heart after myocardial injury. Circulation 2005, 112:I173-I177.
187. Zhang P., Zhang H., Wang H., Wei Y., Hu S. Artificial matrix helps neonatal cardiomyocytes restore injured myocardium in rats. Artif Organs 2006, 30:86-93.
188. Laflamme M.A., Chen K.Y., Naumova A.V., Muskheli V., Fugate J.A., Dupras S.K., et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol 2007, 25:1015-1024.
189. Padin-Iruegas M.E., Misao Y., Davis M.E., Segers V.F.M., Esposito G., Tokunou T., et al. Cardiac progenitor cells and biotinylated insulin-like growth factor-1 nanofibers improve endogenous and exogenous myocardial regeneration after infarction. Circulation 2009, 120:876-887.
190. Lin Y.D., Yeh M.L., Yang Y.J., Tsai D.C., Chu T.Y., Shih Y.Y., et al. Intramyocardial peptide nanofiber injection improves postinfarction ventricular remodeling and efficacy of bone marrow cell therapy in pigs. Circulation 2010, 122:S132-S141.
191. Wang T., Jiang X.-J., Tang Q.-Z., Li X.-Y., Lin T., Wu D.-Q., et al. Bone marrow stem cells implantation with a-cyclodextrin/MPEG- PCL-MPEG hydrogel improves cardiac function after myocardial infarction. Acta Biomater 2009, 5:2939-2944.
192. Kraehenbuehl T.P., Ferreira L.S., Hayward A.M., Nahrendorf M., Van der Vlies A.J., Vasile E., et al. Human embryonic stem cell-derived microvascular grafts for cardiac tissue preservation after myocardial infarction. Biomaterials 2011, 32:1102-1109.
193. Wang H., Liu Z., Li D., Guo X., Kasper F.K., Duan C., et al. Injectable biodegradable hydrogels for embryonic stem cell transplantation: improved cardiac remodelling and function of myocardial infarction. JCell Mol Med 2012, 16:1310-1320.
194. Wu J., Zeng F., Huang X.-P., Chung J.C.Y., Konecny F., Weisel R.D., et al. Infarct stabilization and cardiac repair with a VEGF-conjugated, injectable hydrogel. Biomaterials 2011, 32:579-586.
195. Wang T., Wu D.Q., Jiang X.J., Zhang X.Z., Li X.Y., Zhang J.F., et al. Novel thermosensitive hydrogel injection inhibits post-infarct ventricle remodelling. Eur J Heart Fail 2009, 11:14-19.
196. Fujimoto K.L., Ma Z., Nelson D.M., Hashizume R., Guan J., Tobita K., et al. Synthesis, characterization and therapeutic efficacy of a biodegradable, thermoresponsive hydrogel designed for application in chronic infarcted myocardium. Biomaterials 2009, 30:4357-4368.
197. Wall S.T., Yeh C.-C., Tu R.Y.K., Mann M.J., Healy K.E. Biomimetic matrices for myocardial stabilization and stem cell transplantation. JBiomed Mater Res A 2010, 95:1055-1066.
198. Chachques J.C., Azarine A., Mousseaux E., Serafi El M., Cortes-Morichetti M., Carpenter A. MRI evaluation of local myocardial treatments: epicardial versus endocardial (cell-fix catheter) injections. JInterv Cardiol 2007, 20:188-196.
199. Dib N., Campbell A., Jacoby D.B., Zawadzka A., Ratliff J., Miedzybrocki B.M., et al. Safety and feasibility of percutaneous autologous skeletal myoblast transplantation in the coil-infarcted swine myocardium. JPharmacol Toxicol Methods 2006, 54:71-77.
200. Wall S.T., Walker J.C., Healy K.E., Ratcliffe M.B., Guccione J.M. Theoretical impact of the injection of material into the myocardium: a finite element model simulation. Circulation 2006, 114:2627-2635.
201. Jackson B.M., Gorman J.H., Salgo I.S., Moainie S.L., Plappert T., St John-Sutton M., et al. Border zone geometry increases wall stress after myocardial infarction: contrast echocardiographic assessment. Am J Physiol Heart Circ Physiol 2003, 284:H475-H479.
202. Cornwell K.G., Lei P., Andreadis S.T., Pins G.D. Crosslinking of discrete self-assembled collagen threads: effects on mechanical strength and cell-matrix interactions. JBiomed Mater Res 2006, 80A:362-371.
203. Bhana B., Iyer R.K., Chen W.L.K., Zhao R., Sider K.L., Likhitpanichkul M., et al. Influence of substrate stiffness on the phenotype of heart cells. Biotechnol Bioeng 2010, 105:1148-1160.
204. Engler A.J., Sen S., Sweeney H.L., Discher D.E. Matrix elasticity directs stem cell lineage specification. Cell 2006, 126:677-689.
205. Sharifi S., Blanquer S.B.G., van Kooten T.G., Grijpma D.W. Biodegradable nanocomposite hydrogel structures with enhanced mechanical properties prepared by photo-crosslinking solutions of poly(trimethylene carbonate)-poly(ethylene glycol)-poly(trimethylene carbonate) macromonomers and nanoclay particles. Acta Biomater 2012, 8:4233-4243.
206. Murphy C.M., Haugh M.G., O'Brien F.J. The effect of mean pore size on cell attachment, proliferation and migration in collagen-glycosaminoglycan scaffolds for bone tissue engineering. Biomaterials 2010, 31:461-466.
207. Al-Shamkhani A., Duncan R. Radioiodination of alginate via covalently-bound tyrosinamide allows monitoring of its fate invivo. JBioact Compat Polym 1995, 10:4-13.
208. Kong H.-J., Alsberg E., Kaigler D., Lee K.-Y., Mooney D.J. Controlling degradation of hydrogels via the size of crosslinked junctions. Adv Mater 2004, 16:1917-1921.
209. Bouhadir K.H., Lee K.Y., Alsberg E., Damm K.L., Anderson K.W., Mooney D.J. Degradation of partially oxidized alginate and its potential application for tissue engineering. Biotechnol Prog 2001, 17:945-950.
210. Yu J., Gu Y., Du K.T., Mihardja S., Sievers R.E., Lee R.J. The effect of injected RGD modified alginate on angiogenesis and left ventricular function in a chronic rat infarct model. Biomaterials 2009, 30:751-756.
211. Yu J., Christman K.L., Chin E., Sievers R.E., Saeed M., Lee R.J. Restoration of left ventricular geometry and improvement of left ventricular function in a rodent model of chronic ischemic cardiomyopathy. JThorac Cardiovasc Surg 2009, 137:180-187.
212. Kim I.-Y., Seo S.-J., Moon H.-S., Yoo M.-K., Park I.-Y., Kim B.-C., et al. Chitosan and its derivatives for tissue engineering applications. Biotechnol Adv 2008, 26:1-21.
213. Hirano S., Tsuchida H., Nagao N. N-acetylation in chitosan and the rate of its enzymic hydrolysis. Biomaterials 1989, 10:574-576.
214. Ishihara M., Nakanishi K., Ono K., Sato M., Kikuchi M., Saito Y., et al. Photocrosslinkable chitosan as a dressing for wound occlusion and accelerator in healing process. Biomaterials 2002, 23:833-840.
215. Chenite A., Chaput C., Wang D., Combes C., Buschmann M.D., Hoemann C.D., et al. Novel injectable neutral solutions of chitosan form biodegradable gels in situ. Biomaterials 2000, 21:2155-2161.
216. Rosenblatt J., Devereux B., Wallace D.G. Injectable collagen as a pH-sensitive hydrogel. Biomaterials 1994, 15:985-995.
217. Williams B.R., Gelman R.A., Poppke D.C., Piez K.A. Collagen fibril formation. JBiol Chem 1978, 253:6578-6585.
218. Achilli M., Mantovani D. Tailoring mechanical properties of collagen-based scaffolds for vascular tissue engineering: the effects of pH, temperature and ionic strength on gelation. Polymers 2010, 2:664-680.
219. Breen A., O'Brien T., Pandit A. Fibrin as a delivery system for therapeutic drugs and biomolecules. Tissue Eng Part B Rev 2009, 15:201-214.
220. Kubota K., Kogure H., Masuda Y., Toyama Y., Kita R., Takahashi A., et al. Gelation dynamics and gel structure of fibrinogen. Colloids Surf B Biointerfaces 2004, 38:103-109.
221. Rowe S.L., Lee S., Stegemann J.P. Influence of thrombin concentration on the mechanical and morphological properties of cell-seeded fibrin hydrogels. Acta Biomater 2007, 3:59-67.
222. Bootle-Wilbraham C.A., Tazzyman S., Thompson W.D., Stirk C.M., Lewis C.E. Fibrin fragment E stimulates the proliferation, migration and differentiation of human microvascular endothelial cells invitro. Angiogenesis 2001, 4:269-275.
223. Guo H.-D., Wang H.-J., Tan Y.-Z., Wu J.-H. Transplantation of marrow-derived cardiac stem cells carried in fibrin improves cardiac function after myocardial infarction. Tissue Eng Part A 2010, 17:45-58.
224. Christman K.L., Vardanian A.J., Fang Q., Sievers R.E., Fok H.H., Lee R.J. Injectable fibrin scaffold improves cell transplant survival, reduces infarct expansion, and induces neovasculature formation in ischemic myocardium. JAm Coll Cardiol 2004, 44:654-660.
225. Burdick J.A., Prestwich G.D. Hyaluronic acid hydrogels for biomedical applications. Adv Mater 2011, 23:H41-H56.
226. Stern R., Asari A.A., Sugahara K.N. Hyaluronan fragments: an information-rich system. Eur J Cell Biol 2006, 85:699-715.
227. Kim J., Kim I.S., Cho T.H., Lee K.B., Hwang S.J., Tae G., et al. Bone regeneration using hyaluronic acid-based hydrogel with bone morphogenic protein-2 and human mesenchymal stem cells. Biomaterials 2007, 28:1830-1837.
228. Yoon S.J., Fang Y.H., Lim C.H., Kim B.S., Son H.S., Park Y., et al. Regeneration of ischemic heart using hyaluronic acid-based injectable hydrogel. JBiomed Mater Res 2009, 91B:163-171.
229. van Dijk-Wolthuis W., Hoogeboom J., Van Steenbergen M.J., Tsang S., Hennink W.E. Degradation and release behavior of dextran-based hydrogels. Macromolecules 1997, 30:4639-4645.
230. Laflamme M.A., Gold J., Xu C., Hassanipour M., Rosler E., Police S., et al. Formation of human myocardium in the rat heart from human embryonic stem cells. Am J Pathol 2005, 167:663-671.
231. Hughes C.S., Postovit L.M., Lajoie G.A. Matrigel: a complex protein mixture required for optimal growth of cell culture. Proteomics 2010, 10:1886-1890.
232. Zhang S., Holmes T.C., DiPersio C.M., Hynes R.O., Su X., Rich A. Self-complementary oligopeptide matrices support mammalian cell attachment. Biomaterials 1995, 16:1385-1393.
233. Hsieh P.C.H., Davis M.E., Gannon J., MacGillivray C., Lee R.T. Controlled delivery of PDGF-BB for myocardial protection using injectable self-assembling peptide nanofibers. JClin Invest 2006, 116:237-248.
234. Davis M.E., Hsieh P.C., Takahashi T., Song Q., Zhang S., Kamm R.D., et al. Local myocardial insulin-like growth factor 1 (IGF-1) delivery with biotinylated peptide nanofibers improves cell therapy for myocardial infarction. Proc Natl Acad Sci U S A 2006, 103:8155-8160.
235. Li Z., Guan J. Hydrogels for cardiac tissue engineering. Polymers 2011, 3:740-761.
236. Wu D.-Q., Wang T., Lu B., Xu X.-D., Cheng S.-X., Jiang X.-J., et al. Fabrication of supramolecular hydrogels for drug delivery and stem cell encapsulation. Langmuir 2008, 24:10306-10312.
237. Jiang X.-J., Wang T., Li X.-Y., Wu D.-Q., Zheng Z.-B., Zhang J.-F., et al. Injection of a novel synthetic hydrogel preserves left ventricle function after myocardial infarction. JBiomed Mater Res A 2009, 90:472-477.
238. Kraehenbuehl T.P., Zammaretti P., Van der Vlies A.J., Schoenmakers R.G., Lutolf M.P., Jaconi M.E., et al. Three-dimensional extracellular matrix-directed cardioprogenitor differentiation: systematic modulation of a synthetic cell-responsive PEG-hydrogel. Biomaterials 2008, 29:2757-2766.
239. Lee B.H., Vernon B. In situ-gelling, erodible N-isopropylacrylamide copolymers. Macromol Biosci 2005, 5:629-635.
240. Li X.-Y., Wang T., Jiang X.-J., Lin T., Wu D.-Q., Zhang X.-Z., et al. Injectable hydrogel helps bone marrow-derived mononuclear cells restore infarcted myocardium. Cardiology 2010, 115:194-199.
241. Iacobellis G. Epicardial and pericardial fat: close, but very different. Obes (Silver Spring) 2009, 17:625. authorreply626-627.
242. Dinsmore J.H., Dib N. Stem cell therapy for the treatment of acute myocardial infarction. Cardiol Clin 2010, 28:127-138.